IP Library Granted Patent US 8,642,830
Granted Patent B2
US 8,642,830 · App. 13/541,607 · Granted Feb 4, 2014

Drug deactivation method

Inventors: Scott Albert Uhland (Redwood City, CA); Eric Peeters (Mountain View, CA); Francisco E. Torres (San Jose, CA); Philipp Helmut Schmaelzle (Los Altos, CA)
Assignee: Palo Alto Research Center Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,642,830
App. No.
13/541,607
Granted
Feb 4, 2014
Kind
B2
Abstract

A drug deactivation system according to some embodiments includes at least one drug-retaining region of a drug delivery device and at least one energy source coupled to the at least one drug-retaining region. The at least one drug-retaining region may be configured to retain a drug. The at least one energy source may be configured to transmit energy to the drug. The drug is capable of being rendered ineffective in the presence of the transmitted energy.

Claims (10)

1. A method of deactivating a drug, the method comprising:

retaining a drug within a drug-retaining region of a drug delivery device, wherein the drug is capable of being rendered ineffective in the presence of the transmitted energy; and

transmitting energy to the drug retained within the drug-retaining region of the drug delivery device.

2. The method of claim 1 , wherein transmitting the energy includes transmitting at least one type of energy selected from the group consisting of mechanical energy, electrical energy, thermal energy, and electromagnetic radiation.

3. The method of claim 2 , wherein transmitting the energy comprises transmitting at least one type of electromagnetic radiation selected from the group consisting of microwave radiation, infrared radiation, visible light and ultraviolet radiation.

4. The method of claim 2 , wherein transmitting the energy comprises:

transmitting electrical energy to an absorbing element contacting the drug; and

absorb at least a portion of the drug retained within the at least one drug-retaining region in the presence of the transmitted electrical energy.

5. The method of claim 2 , wherein transmitting the energy comprises transmitting ultrasonic energy.

6. The method of claim 5 , wherein the ultrasonic energy is configured to crystallize the drug, heat the drug or a combination thereof.

Continuity (2)
Division 12357224 · Jan 21, 2009
Related Publication 20120277514A1 · Nov 1, 2012